

Corresponding author(s):	Alexander Visekruna
Last undated by author(s):	lan 16, 2019

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

_				
5	ta	ıtı	ıst	ics

For	all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.		
n/a	Confirmed			
	The exact sam	ple size (n) for each experimental group/condition, given as a discrete number and unit of measurement		
	A statement o	on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly		
	The statistical Only common to	test(s) used AND whether they are one- or two-sided ests should be described solely by name; describe more complex techniques in the Methods section.		
	A description	of all covariates tested		
	A description	of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons		
	A full descript AND variation	ion of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)		
	For null hypot Give P values as	hesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted exact values whenever suitable.		
\boxtimes	For Bayesian a	analysis, information on the choice of priors and Markov chain Monte Carlo settings		
\boxtimes	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes			
\boxtimes	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated			
		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.		
Software and code				
Policy information about <u>availability of computer code</u>				
Da	ata collection	FACSDiva software (version 8.1, BD Biosciences) was used to collect FACS samples.		

3.4.3) was used for analysis of RNA-Seq data. Agilent Seahorse Wave software was used for metabolic studies. For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

FlowJo (version 10) was used to analyze flow cytometry data. GraphPad Prism 5 was used for graphs and statistical analysis. R (version

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

RNA-seq data have been deposited in ArrayExpress Archive of Functional Genomics Data under the accession codes E-MTAB-6114 for Th17 cells [https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6114/] and E-MTAB-6115 for Bregs [https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6115/]. All other relevant data are available from authors upon reasonable request.

Field-spe	cific reporting		
Please select the or	ne below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.		
\times Life sciences	Behavioural & social sciences Ecological, evolutionary & environmental sciences		
For a reference copy of t	he document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf		
Life scier	ices study design		
All studies must dis	close on these points even when the disclosure is negative.		
Sample size	To determine sample size for immunological studies, power analysis (power = 80 % and significance level = 5 %) was performed. Unless otherwise indicated, animal experiments were performed using 6-10 mice per group.		
Data exclusions	No data were excluded from the analyses.		
Replication	All experimental findings were successfully reproduced by each atempt.		
Randomization	Animals were randomly assigned to mock or pentanoate treatment. Animals of same sex and age were used to control for covariates.		
Blinding	Investigators were not blinded.		
Materials & exp n/a Involved in th Antibodies Eukaryotic Palaeontol Animals an	Cell lines ChIP-seq Flow cytometry Day MRI-based neuroimaging d other organisms earch participants		
Antibodies used	The following antibodies were used: anti-CD4 (BioLegend, clone GK1.5, #100402, 1:400), anti-CD4 (BD Biosciences, clone RM4-5, #560468, 1:500), anti-CD19 (Thermo Fisher Scientific, clone eBio1D3, #45-0193-82, 1:400), anti-CD8 (BD Biosciences, clone 53-6.7, #560776, 1:500). anti-IL-17A (Thermo Fisher Scientific, clone eBio17B7, #17-7177-81,1:200), anti-IFN-g (Thermo Fisher Scientific, clone XMG1.2, #17-7311-82, 1:500), anti-phospho-AKTSer437 (#9271, Cell Signaling Technology, 1:1000), anti-phospho-AKTThr308 (#13038, CST, 1:1000), anti-total AKT (#9272, CST, 1:1000), anti-phospho-mTORSer2448 (#5536, CST, 1:1000), anti-total mTOR (#2983, CST, 1:1000), anti-phosphoS6KT389 (#9205, CST, 1:1000), anti-total S6K (#9202, CST, 1:1000), anti-phosphoS6S235/236 (#4858, CST, 1:1000) and anti-total S6 (#2217, CST, 1:1000).		
Validation	Validation statements for antibodies are available on the manufacturer's website.		
Animals and	other organisms		
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research			
Laboratory anima	Female mice with age between 8-12 weeks were used for this study. WT mice on C57BL/6 background were purchased from Charles River Laboratories. Germ-free mice were reared in sterile plastic isolators and were monitored biweekly for sterility. FIR × tiger reporter mice were bred at the animal facility of the Biomedical Research Center, University of Marburg, Germany.		

The study did not involve wild animals.

The study did not involve the samples collected from the field.

Wild animals

Field-collected samples

Ethics oversight

Animal work was approved by Regierungspräsidium Gießen, Germany under project numbers 70/2014 and EX7-2015.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation

Lymph node- and spleen-derived cells were collected in RPMI, spun down at 1500 RCF at 4 degrees. T cells were isolated with negative selection and were then washed with ice-cold FACS buffer and stained using the antibodies described above for 20 minutes. For intracellular staining, T cells were restimulated with 50 ng/ml PMA and 750 ng/ml ionomycin in the presence of 10 μ g/ml brefeldin A for 4 hours. After fixation and permeabilisation, the cells were stained with antibodies.

Instrument

FACSCalibur cytometer and BD FACSAria III cell sorter (both BD Biosciences)

Software

FlowJo analysis software (TreeStar)

Cell population abundance

The purity of T cells and B cells was determined by using anti-CD4 and anti-CD19 antibodies, respectively (over 96 % purity).

Gating strategy

Gating strategy to sort and analyze T lymphocytes and Bregs is provided in Supplementary Figure 7. In brief, lymphocytes were gated using SSC-A and FSC-A, and the CD4+ T cells were gated using anti-CD4 antibody. For Bregs, anti-CD19 antibody was used.

| Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.